Acute lymphoblastic leukemia

ALL involves immature lymphoid cells in marrow, blood or other sites. Flow cytometry establishes B- or T-lineage and relevant treatment targets. Chromosome and molecular tests identify subgroups such as BCR::ABL1-positive, KMT2A-rearranged, ETV6::RUNX1 and hyperdiploid B-ALL. These findings are interpreted with age, presentation and response.

Philadelphia-like ALL is not the same as BCR::ABL1-positive ALL: additional testing is needed to identify the underlying kinase alteration and whether a matched treatment or trial is relevant. Early T-cell precursor ALL is a T-lineage phenotype with distinct assessment needs, not an indication to use B-cell-directed drugs.

The diagnostic record should include blood counts, marrow morphology, flow cytometry, genetics and baseline organ function. The team assesses central nervous system involvement and, when relevant, testicular or other disease sites. Lumbar puncture timing must account for bleeding risk and the treatment protocol.

ALL does not use the usual solid-cancer stage I–IV framework. Risk groups combine disease genetics, initial burden, age and early response. Pediatric and adult protocols define risk differently; a “standard-risk” label does not mean no treatment is needed.

MRD testing may use flow cytometry, molecular assays or sequencing. Compare results with the method's sensitivity, marrow quality and protocol time point. Persistent or returning MRD can trigger a change in treatment or transplant assessment before obvious relapse; different assays cannot always be substituted for one another.

An MRD-negative remission remains a treatment milestone rather than permission to stop. In the randomized E1910 study, adults with BCR::ABL1-negative B-ALL who were MRD-negative still benefited from adding blinatumomab to consolidation. The practical question is what the result changes within the whole protocol.

Treatment typically proceeds through induction, consolidation/intensification and, for many regimens, maintenance. Intrathecal and other CNS-directed treatment is essential even when no CNS leukemia is detected. Cranial radiation is reserved for selected situations rather than given to everyone.

Children and many fit adolescents or young adults receive pediatric or pediatric-inspired protocols, with careful management of asparaginase toxicity. Older adults or patients with substantial comorbidity may need lower-intensity approaches incorporating immunotherapy. Fitness and disease biology should guide the plan together.

The current US label includes blinatumomab in consolidation of multiphase chemotherapy for CD19-positive, Philadelphia-negative B-cell precursor ALL from age one month. Its roles in MRD-positive remission and relapsed/refractory disease have separate criteria. Continuous infusion, pump support and monitoring for neurological toxicity and cytokine release syndrome are practical parts of care.

Pediatric evidence includes AALL1731, which added blinatumomab for specified standard-risk groups, and the September 2026 AIEOP-BFM ALL 2017 report, which replaced two intensive chemotherapy cycles in newly diagnosed high-risk B-ALL and improved event-free survival. Adding and replacing treatment are different strategies; neither means abandoning the remaining chemotherapy or CNS plan.

BCR::ABL1-positive ALL requires a BCR::ABL1-directed tyrosine kinase inhibitor as part of the treatment strategy. The US ponatinib label includes combination with chemotherapy for newly diagnosed adults. Drug selection considers mutation findings, cardiovascular risk, interactions and the complete protocol.

TKI–blinatumomab approaches can substantially reduce conventional systemic chemotherapy in selected specialist protocols. Prospective phase II results and a 2026 propensity-score comparison are encouraging, but the latter is not a randomized trial. CNS protection remains necessary, and the need for transplantation depends on molecular response and risk rather than the Philadelphia chromosome alone.

Relapse should prompt renewed lineage, antigen and genetic assessment. Prior CD19-directed treatment can affect subsequent CD19 options. Blinatumomab, CD22-directed inotuzumab ozogamicin, CAR-T, kinase inhibitors for relevant disease and clinical trials are selected according to the relapse setting and the intended next step.

The US inotuzumab indication includes relapsed/refractory CD22-positive B-cell precursor ALL in adults and children aged one year or older. Liver sinusoidal obstruction, particularly around subsequent transplantation, affects sequencing. Revumenib provides a US-labeled option from age one year for relapsed/refractory acute leukemia with a KMT2A translocation; it is not a treatment for all ALL and requires monitoring for differentiation syndrome and other toxicities.

These products are not interchangeable by age or evidence. Manufacturing time, bridging treatment, disease burden, neurological toxicity, cytokine release syndrome and infection support all affect feasibility. Local authorization and center acceptance must be confirmed for the specific patient.

Allogeneic transplantation is considered for selected high-risk, persistently MRD-positive or relapsed patients. Whether to transplant after CAR-T depends on the product, depth and durability of response, prior transplant and individual risk; it is neither obligatory for everyone nor automatically unnecessary.

T-ALL is treated with T-lineage protocols; nelarabine is relevant in defined settings. B-cell-directed blinatumomab and CD19 CAR-T should not be transferred to T-ALL simply because both are called ALL. Relapsed T-ALL often requires trial assessment and a potential transplant strategy.

CD7 CAR-T approaches are advancing. The 2026 universal base-edited CAR7 report described 11 treated patients and enabled transplantation in most; earlier WU-CART-007 also produced prospective trial evidence. These remain study-specific results, with infection, immune suppression and antigen escape concerns, not proof that every patient can access a curative off-the-shelf treatment.

Infection prevention, transfusion support and tumor-lysis management begin early. Asparaginase-related pancreatitis, thrombosis or allergy, steroid effects and treatment-related neuropathy need prompt reporting. Discuss fertility before treatment when feasible, without delaying urgent care, and plan childhood growth, learning and endocrine follow-up.

Bring lineage and antigen results, complete genetics, dated MRD reports with methods, CNS findings, prior drug exposure and toxicities, transplant information and current infection status. Ask what the next treatment is intended to achieve and what response would change the transplant or maintenance plan.